Want to see PHAR full AI Analyst Report?
PHAR Stock Chart & Stats
$12.62
-$0.55(-4.21%)
At close: 4:00 PM EDT
$12.62
-$0.55(-4.21%)
Day’s Range― - ―
52-Week Range$9.62 - $21.34
Previous Close$12.62
Volume5.37K
Average Volume (3M)5.77K
Market Cap
$715.13M
Enterprise Value$1.08K
Total Cash (Recent Filing)$158.28M
Total Debt (Recent Filing)$113.30M
Price to Earnings (P/E)68.9
Beta0.43
Next Earnings
Nov 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding70,778,120
10 Day Avg. Volume5,378
30 Day Avg. Volume5,772
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)4.55
Price to Sales (P/S)3.35
P/FCF Ratio25.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$38.00Price Target Upside201.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.25
Revenue Forecast (FY)$405.31M
Bulls Say, Bears Say
Bulls Say
Joenja Commercial Growth & Label ExpansionSustained high‑growth trajectory for Joenja across geographies and planned pediatric label expansion meaningfully broadens the addressable ultra‑rare APDS market. Durable underlying demand, international launches and pediatric approval extend recurring revenue potential and reduce dependence on a single product.
Very High Gross MarginsBiologic product economics yield very high gross margins, which provide structural operating leverage as sales scale. High gross profitability supports sustainable adjusted earnings once topline stabilizes and shields core cash generation from moderate pricing pressure in rare-disease markets.
Manageable Leverage And RunwayBalance sheet shows moderate leverage and a multi‑quarter cash buffer, reducing near‑term refinancing risk and enabling continuation of pivotal trials and launches. Manageable debt and positive trailing cash generation give the company time to convert pipeline catalysts into durable revenue.
Bears Say
RUCONEST Revenue PressureRUCONEST remains a large and established revenue source; sustained year‑over‑year declines due to competition and strategic market exits weaken core cash flow and increase reliance on newer products. Structural pressure on the legacy franchise raises execution risk for commercial recovery.
Lowered 2026 Revenue GuidanceA material downward guidance revision signals weaker demand visibility and constrains the firm's ability to leverage fixed costs. Persistent top‑line softness limits long‑term margin expansion and increases uncertainty around funding allocations for commercial rollouts and late‑stage development.
Cash Flow Volatility & One‑off ImpairmentsInventory impairments and restructuring provisions reveal operational and manufacturing execution risk; combined with recent operating cash outflows, this volatility raises the likelihood of pressured free cash flow. That heightens refinancing or dilution risk and could force prioritization among pipeline programs.
Pharming Group News
PHAR FAQ
What was Pharming Group Nv’s price range in the past 12 months?
Pharming Group Nv lowest stock price was $9.62 and its highest was $21.34 in the past 12 months.
What is Pharming Group Nv’s market cap?
Pharming Group Nv’s market cap is $715.13M.
When is Pharming Group Nv’s upcoming earnings report date?
Pharming Group Nv’s upcoming earnings report date is Nov 05, 2026 which is in 95 days.
How were Pharming Group Nv’s earnings last quarter?
Pharming Group Nv released its earnings results on Jul 30, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.063 by -$0.043.
Is Pharming Group Nv overvalued?
According to Wall Street analysts Pharming Group Nv’s price is currently Undervalued.
Does Pharming Group Nv pay dividends?
Pharming Group Nv does not currently pay dividends.
What is Pharming Group Nv’s EPS estimate?
Pharming Group Nv’s EPS estimate is 0.11.
How many shares outstanding does Pharming Group Nv have?
Pharming Group Nv has 70,778,120 shares outstanding.
What happened to Pharming Group Nv’s price movement after its last earnings report?
Pharming Group Nv reported an EPS of $0.02 in its last earnings report, missing expectations of $0.063. Following the earnings report the stock price went down -10.491%.
Which hedge fund is a major shareholder of Pharming Group Nv?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (201.11% Upside)
$38.00 (201.11% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Pharming Group Nv
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum for Joenja (robust percentage growth, geographic and pediatric expansion) and encouraging underlying RUCONEST demand indicators (active patient base ~93%, sequential revenue rebound) are offset by near-term headwinds — RUCONEST year-over-year revenue declines, a $30M revenue guidance reduction, operating cash outflows, and a manufacturing inventory impairment. Management emphasized cost discipline, positive operating profit in Q2, sufficient cash to fund the pipeline, and several upcoming clinical catalysts (leniolisib Phase II readouts in Q4, napazimone in 2027) that could materially change the trajectory. Given the balance of meaningful near-term challenges against several concrete growth drivers and pipeline milestones, the overall tone is cautious and balanced.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$38.00
▲(201.11% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.08% Other Institutional Investors
99.90% Public Companies and
Individual Investors